ArticleCancer research communications2025

A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors.

Christopher H Lieu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.